Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | DNM1L | O00429 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724346 | 0.86 | HPGD (0.61) | HPGDNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5724501 | 0.81 | HPGD (0.53) | HPGDNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5723782 | 0.77 | HPGD (0.53) | HPGDNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5723668 | 0.75 | KDM4E (0.48) | HPGDSMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL5723789 | 0.72 | HPGD (0.52) | HPGDNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5724067 | 0.71 | POLB (0.41) | HPGDNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5724038 | 0.71 | PARP1 (0.38) | MAPTALDH1A1HTT | |
| SCHEMBL5723956 | 0.71 | HRH3 (0.33) | DNM1L | |
| SCHEMBL5724161 | 0.70 | DNM1L (0.36) | DNM1L | |
| SCHEMBL5724215 | 0.69 | OGA (0.42) | HPGDNPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148357-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | SCHERING AG (DE) | 2006-12-12 | — | — | US | disclosed |
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040147535-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-07-29 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | HPGD 1268/4885NPC1 383/4885RAB9A 3028/4885 |
| US-20040147535-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | FLT4, KDR, FLT1 | HPGD 2498/4885NPC1 4839/4885RAB9A 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.